The Role of USP and NABP in Pharmacy Compounding Standards

Two institutions you will see named

When FDA’s Pharmacy Compounding Advisory Committee publishes rosters, seats often include representatives connected to:

- **USP (United States Pharmacopeia)** — standards-setting organization whose monographs and compounding-related standards are widely referenced in pharmacy quality systems

- **NABP (National Association of Boards of Pharmacy)** — association of state boards of pharmacy; appears in compounding policy discussions as a pharmacy-regulatory community voice

Neither organization “approves drugs” the way FDA approves NDAs. Their relevance is standards, practice norms, and regulatory coordination.

Why standards bodies matter in bulks debates

Bulk-substance listing decisions sit at the intersection of chemistry, pharmacy practice, and public health. Standards organizations contribute vocabulary and expectations around identity, quality, and compounding practice — the same themes that appear in FDA’s characterization and safety factors.

Having USP- or NABP-linked expertise in the room is one way advisory meetings stay connected to those practice standards.

What they are not

- They are not a substitute for FDA final rules

- They are not a Certificate of Analysis for a commercial lot

- They are not an endorsement of any research supplier

Reading roster line items usefully

When a news piece lists committee affiliations, translate each seat into a function:

- Clinical practice seat → bedside / clinic perspective

- Pharmacy seat → dispensing and compounding operations perspective

- USP seat → standards and monograph perspective

- NABP seat → state board / pharmacy regulation perspective

- Industry representative → typically non-voting industry liaison

Functional reading beats conspiracy reading — and keeps educational content focused on process.

*For research use only. Not for human or animal consumption.*